Search clinical trials for: bevacizumab erlotinib hydrochloride

Total 10071 results

University of California, San Francisco

Completed

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (AVF4120s)

Glioblastoma | Gliosarcoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

Hepatocellular Carcinoma | Liver Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Malignant Brain Tumor | Brain Stem Glioma,

France
Kansas City Veteran Affairs Medical Center

Unknown

Erlotinib in Treating Patients With Barrett Esophagus

Esophageal Cancer | Precancerous Condition

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Sanofi; Genentech, Inc.

Completed

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Hoffmann-La Roche

Completed

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Solid Tumor

Spain, Russian Federation, France, Japan, South Africa, Latvia, Serbia, Italy
National Cancer Institute (NCI)

Active, not recruiting

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

HLRCC | Sporadic Papillary Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Paula Silverman, MD
National Cancer Institute (NCI)

Completed

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Breast Cancer

United States
Roswell Park Cancer Institute

Completed

Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

Esophageal Cancer

United States
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

Lung Cancer

United Kingdom
University College, London
Roche Pharma AG; Cancer Research UK

Terminated

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases (TACTIC)

Lung Cancer | Metastatic Cancer

United Kingdom
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

Canada
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditions

United States
Guangdong Association of Clinical Trials

Unknown

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

NSCLC

China
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

Greece
University of Arkansas
Genentech, Inc.

Completed

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Spain
Dana-Farber Cancer Institute
Massachusetts General Hospital; University of Chicago

Completed

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Mesothelioma

United States
David M. Brizel, MD
Genentech, Inc.; OSI Pharmaceuticals

Completed

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Head and Neck Cancer | Pharynx Cancer

United States
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
Advenchen Laboratories, LLC

Available

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer | Sarcoma,Soft Tissue
Fudan University

Unknown

Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult | High Grade Sarcoma

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Pancreatic Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

Canada
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genentech...

Completed

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Rectal Cancer | Adenocarcinoma of the Rectum

United States
SCRI Development Innovations, LLC
Genentech, Inc.

Completed

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Neoplasm, Unknown Primary

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Stage IV Ovarian Epithelial Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma... and other conditions

United States
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Sun Yat-sen University

Unknown

Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy

Head and Neck Cancer

China
Samsung Medical Center

Completed

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Lung Neoplasms | Neoadjuvant Therapy | Erlotinib

Korea, Republic of
Sidney Kimmel Cancer Center at Thomas Jefferson...
Genentech, Inc.

Completed

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Melanoma | Head and Neck Cancer | Parotid Gland Cancer | Thyroid Gland Cancer | Stage IV Head and Neck Cancer

United States
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China

Search clinical trials for: bevacizumab erlotinib hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations